Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Moderate Buy consensus: Nine analysts cover Lexeo Therapeutics (NASDAQ:LXEO) — 1 sell, 7 buy, 1 strong buy — with an average 12‑month price target of about $18.88.
• Insider sale: CEO Richard Nolan Townsend sold 55,000 shares under a Rule 10b5‑1 plan at an average $5.69 on April 6, cutting his stake by 13.92%; insiders have sold 68,189 shares in the past 90 days and now own 5.30% of the company.
• Institutional activity and market data: Institutions own ~60.67% of the stock with large increases from Millennium Management and AQR, the shares trade near $5.77 (market cap ~$427.5M), and Lexeo slightly beat the quarter with EPS of ($0.27) vs. ($0.32) expected.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $18.8750.

A number of analysts have recently issued reports on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Lexeo Therapeutics in a report on Friday, April 17th. Chardan Capital restated a "buy" rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, January 13th. HC Wainwright reduced their target price on Lexeo Therapeutics from $13.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, January 13th. Finally, Wall Street Zen lowered Lexeo Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday.

Insider Activity

In related news, CEO Richard Nolan Townsend sold 55,000 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $5.69, for a total transaction of $312,950.00. Following the completion of the sale, the chief executive officer directly owned 340,106 shares in the company, valued at approximately $1,935,203.14. This trade represents a 13.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,189 shares of company stock worth $397,156 in the last ninety days. 5.30% of the stock is currently owned by company insiders.

Institutional Trading of Lexeo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LXEO. AQR Capital Management LLC raised its holdings in shares of Lexeo Therapeutics by 370.0% during the first quarter. AQR Capital Management LLC now owns 50,337 shares of the company's stock worth $175,000 after acquiring an additional 39,627 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Lexeo Therapeutics by 654.8% during the first quarter. Millennium Management LLC now owns 1,071,489 shares of the company's stock worth $3,718,000 after acquiring an additional 929,538 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Lexeo Therapeutics during the first quarter worth $85,000. Rhumbline Advisers raised its holdings in shares of Lexeo Therapeutics by 19.8% during the first quarter. Rhumbline Advisers now owns 30,192 shares of the company's stock worth $105,000 after acquiring an additional 4,995 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in shares of Lexeo Therapeutics during the second quarter worth $50,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Stock Up 1.2%

LXEO opened at $5.77 on Friday. The stock has a fifty day moving average of $6.29 and a 200-day moving average of $7.89. The firm has a market capitalization of $427.50 million, a P/E ratio of -2.63 and a beta of 1.53. Lexeo Therapeutics has a 12-month low of $2.43 and a 12-month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its earnings results on Monday, March 30th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.05. On average, analysts expect that Lexeo Therapeutics will post -1.27 earnings per share for the current fiscal year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.